Affinity Selection – Mass Spectrometry screening

The Edelris Discovery ENgine (EDEN), combining our unique Keymical Space™ with our cutting-edge Affinity Selection – Mass Spectrometry (AS-MS) screening platform, increases your return on screening investment.

Outstanding results have been obtained from EDEN on difficult-to-drug targets, setting up new standards for our clients’ quest for innovative ligands. EDEN has a strong track-record of validated hits for different Protein Targets, including GPCR, Protein-Protein interfaces, Transcription Factors, and RNA Targets.

If you are looking for new and relevant chemical matter for your drug targets, EDEN is the best option! Do not hesitate to reach out to us!


Main advantages of the Edelris AS-MS screening platform

  • Straightforward screening setup: Fast track assay development, since AS-MS methods are solution based and do not require immobilization steps.
  • Limited false positives, accelerating direct ligand identification via high resolution mass detection and optimized screens.
  • Our screening deck is assembled without any chemistry limitations, as the compounds do not need any additional and labile tags.
  • Mass-encoded compounds designed and synthesized by EDELRIS, using current medicinal chemistry guidelines.
  • Unique and diverse compound deck (2 Millions) originating from EDELRIS’ own manufactured sp3-rich and diverse Keymical SpaceTM. Very quick re-synthesis of active hits for confirmation as singles using in-house building blocks and team of expert chemists.
  • High flexibility in decks to be screened: You can also opt for the screening of your own corporate decks.
  • The entire process is performed in Edelris laboratories, from target qualification to deliverables sent to clients. This provides high confidence of ligand identification and delivery within 4 months.

In addition, competition assays can be easily carried out using the AS-MS technology and allow to determine whether hits are in exclusive binding with reference compounds. It also enables to classify hits in groups according to their binding sites and mode.

Kd can also be determined allowing for hit ranking according to their target affinity. Applicable targets include GPCRs, Kinases, G-proteins, Transcription factors, Hydrolases, Membrane proteins, PCSK9, Sting, ncRNA riboswitch, cytoskeleton enzymes,…

For more thorough information on AS-MS techniques, consult our perspective article in “Nature Review Chemistry”, co-authored with Allen Annis (Aileron Therapeutics) and Peter Dandliker (Dewpoint Therapeutics), and our review article in “Drug Discovery Today”, co-authored with Jarrod Walsh (AstraZeneca).


Keymical Space™ & Virtual Screening

Structural information has reached a prominent role in drug discovery as a key experimental design tool. The EDEN platform (Edelris Discovery ENgine) relies on Edelris’ proprietary Keymical Space™ (50 Mio original structures) and virtually screens innovative molecular frameworks on challenging targets.

After successful hit identification, the next high-stakes stage is to quickly evaluate the genuine structures in the appropriate bioassays after chemical (re)synthesis. Edelris is at your side to seamlessly transform virtual hits into real samples from the internal know-how embedded in our tangible space.

This approach has already proven successful on several R&D projects conducted on behalf of clients.

Would you like more information about Edelris Solutions and Services?

Christine Kinnaert

Business Development Manager